This is a randomized, multicenter, double-blind, Phase 3 study with 2 parallel groups. The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different dosing regimens of itepekimab monotherapy in Japanese participants aged 18 years or older with chronic rhinosinusitis with nasal polyp(s) (CRSwNP) who are not adequately controlled despite previous surgery and/or treatment with systemic corticosteroid(s) (SCS).
The total study duration par participant is approximately 76 week, including:
* A screening period for up to 4 weeks. * A randomized study intervention period for up to 52 weeks * A post-intervention safety follow-up for up to 20 weeks * The number of visits will be 9 site visits and 20 phone/home visits
Participants must be 18 years of age or older.
Participants with a history of CRSwNP for at least 1 year.
Prior sinonasal surgery for NP.
Worsening symptoms of CRS requiring treatment with SCS within the prior 1 year.
Participants with a history of clinically significant renal, hepatic, metabolic, neurologic, hematologic, ophthalmologic, respiratory (excluding those with asthma and AERD which may be included in the study), gastrointestinal, cardiovascular, cerebrovascular, or other significant medical illness or disorder, which, in the judgment of the Investigator, could interfere with the study or require treatment that might interfere with the study.
Participants who are currently smoking tobacco and/or vaping, or participants in whom smoking/vaping cessation has occurred <6 months. Nicotine replacement therapy and/or noninhaled tobacco product use are not considered current smoking of tobacco.
Participants with a history of a severe systemic hypersensitivity reaction to a mAb.
Participants with conditions/concomitant diseases making them non-evaluable or for the primary efficacy endpoint.
Parallel
Itepekimab (SAR440340)
DrugPharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
Placebo
DrugPharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
Change from baseline in the endoscopic NPS
The Nasal Polyp Score (NPS) is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).
Change from baseline in the NCS
The Nasal Congestion Score (NCS) is scored using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Outcome value is defined as the preceding 28-day average of morning scores recorded in eDiary.
Proportion of NPS responders (defined as participants with improvement by at least 1 points in NPS)
Change from baseline in endoscopic NPS
The NPS is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).
Change from baseline in NCS
The NCS is scored using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Outcome value is defined as the preceding 28-day average of morning scores recorded in eDiary.
Click on the lead sponsor to view all of their trials.
Sanofi
Lead sponsor
Regeneron Pharmaceuticals
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
